Low-dose hepatocyte growth factor gene therapy for diabetes
AssigneeKagoshima University
InventorsKen-ichiro KOSAI, Eriko MATSUDA
Life of this patent
Estimating the term…
Abstract
An agent for protecting and/or regenerating pancreatic β cells in a mammal with diabetes, containing a recombinant viral vector expressing a hepatocyte growth factor (HGF), wherein the agent is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and the viral vector contains a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose is provided by the present invention.
Claims10
-9. (canceled)
A method for treating a mammal with diabetes, comprising administering a recombinant viral vector expressing HGF to the mammal, wherein the viral vector is administered at a dose of 1010-1012 virus particles (vp)/kg body weight, and comprises a nucleic acid encoding HGF downstream of a promoter with transcriptional activity capable of affording a therapeutically effective blood HGF level at said dose.
Dependencies are inferred from the claim text.